nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—Vemurafenib—melanoma	0.149	0.402	CbGbCtD
Tacrolimus—ALB—melanoma	0.137	0.512	CbGaD
Tacrolimus—ABCB1—melanoma	0.13	0.488	CbGaD
Tacrolimus—ALB—Vemurafenib—melanoma	0.0627	0.169	CbGbCtD
Tacrolimus—CYP3A4—Temozolomide—melanoma	0.0358	0.0968	CbGbCtD
Tacrolimus—CYP3A7—Docetaxel—melanoma	0.023	0.0622	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.023	0.0622	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—melanoma	0.0218	0.0588	CbGbCtD
Tacrolimus—CYP3A4—Vemurafenib—melanoma	0.0196	0.053	CbGbCtD
Tacrolimus—CYP3A5—Docetaxel—melanoma	0.0173	0.0467	CbGbCtD
Tacrolimus—ABCB1—Docetaxel—melanoma	0.0112	0.0304	CbGbCtD
Tacrolimus—CYP3A4—Docetaxel—melanoma	0.00674	0.0182	CbGbCtD
Tacrolimus—MTOR—leg—melanoma	0.00563	0.109	CbGeAlD
Tacrolimus—MTOR—hindlimb—melanoma	0.00503	0.0975	CbGeAlD
Tacrolimus—MTOR—appendage—melanoma	0.00431	0.0836	CbGeAlD
Tacrolimus—PPP3CA—hair follicle—melanoma	0.00347	0.0672	CbGeAlD
Tacrolimus—ABCA5—eye—melanoma	0.00256	0.0497	CbGeAlD
Tacrolimus—ABCA5—retina—melanoma	0.00254	0.0492	CbGeAlD
Tacrolimus—MTOR—blood vessel—melanoma	0.0024	0.0466	CbGeAlD
Tacrolimus—Sirolimus—FGF2—melanoma	0.00227	0.77	CrCbGaD
Tacrolimus—ABCA5—mammalian vulva—melanoma	0.00203	0.0394	CbGeAlD
Tacrolimus—MTOR—neck—melanoma	0.00172	0.0333	CbGeAlD
Tacrolimus—PPP3CA—retina—melanoma	0.00171	0.0332	CbGeAlD
Tacrolimus—FKBP1A—neck—melanoma	0.00154	0.03	CbGeAlD
Tacrolimus—ABCA5—head—melanoma	0.00145	0.0282	CbGeAlD
Tacrolimus—PPP3CA—mammalian vulva—melanoma	0.00137	0.0266	CbGeAlD
Tacrolimus—MTOR—eye—melanoma	0.00128	0.0248	CbGeAlD
Tacrolimus—MTOR—retina—melanoma	0.00127	0.0246	CbGeAlD
Tacrolimus—FKBP1A—eye—melanoma	0.00115	0.0223	CbGeAlD
Tacrolimus—FKBP1A—retina—melanoma	0.00114	0.0221	CbGeAlD
Tacrolimus—MTOR—skin of body—melanoma	0.00111	0.0216	CbGeAlD
Tacrolimus—ABCA5—lymph node—melanoma	0.00102	0.0197	CbGeAlD
Tacrolimus—MTOR—mammalian vulva—melanoma	0.00101	0.0197	CbGeAlD
Tacrolimus—FKBP1A—skin of body—melanoma	0.001	0.0194	CbGeAlD
Tacrolimus—PPP3CA—head—melanoma	0.000982	0.019	CbGeAlD
Tacrolimus—FKBP1A—mammalian vulva—melanoma	0.000912	0.0177	CbGeAlD
Tacrolimus—MTOR—head—melanoma	0.000725	0.0141	CbGeAlD
Tacrolimus—PPP3CA—lymph node—melanoma	0.000688	0.0133	CbGeAlD
Tacrolimus—FKBP1A—head—melanoma	0.000652	0.0127	CbGeAlD
Tacrolimus—MTOR—lymph node—melanoma	0.000508	0.00985	CbGeAlD
Tacrolimus—ABCB1—blood vessel—melanoma	0.0005	0.00969	CbGeAlD
Tacrolimus—FKBP1A—lymph node—melanoma	0.000457	0.00886	CbGeAlD
Tacrolimus—Temsirolimus—ABCB1—melanoma	0.000361	0.123	CrCbGaD
Tacrolimus—ORM1—lymph node—melanoma	0.000358	0.00694	CbGeAlD
Tacrolimus—Sirolimus—ABCB1—melanoma	0.000318	0.108	CrCbGaD
Tacrolimus—ALB—lymph node—melanoma	0.000314	0.00608	CbGeAlD
Tacrolimus—ABCB1—retina—melanoma	0.000263	0.00511	CbGeAlD
Tacrolimus—ABCB1—mammalian vulva—melanoma	0.000211	0.00409	CbGeAlD
Tacrolimus—ABCB1—head—melanoma	0.000151	0.00293	CbGeAlD
Tacrolimus—Dry skin—Docetaxel—melanoma	0.000137	0.000864	CcSEcCtD
Tacrolimus—Chest pain—Bleomycin—melanoma	0.000137	0.000862	CcSEcCtD
Tacrolimus—Myalgia—Bleomycin—melanoma	0.000137	0.000862	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Docetaxel—melanoma	0.000137	0.000861	CcSEcCtD
Tacrolimus—Rash—Vemurafenib—melanoma	0.000137	0.00086	CcSEcCtD
Tacrolimus—Mental disorder—Temozolomide—melanoma	0.000137	0.000859	CcSEcCtD
Tacrolimus—Dermatitis—Vemurafenib—melanoma	0.000137	0.000859	CcSEcCtD
Tacrolimus—Back pain—Carmustine—melanoma	0.000136	0.000855	CcSEcCtD
Tacrolimus—Headache—Vemurafenib—melanoma	0.000136	0.000854	CcSEcCtD
Tacrolimus—Erythema—Temozolomide—melanoma	0.000136	0.000854	CcSEcCtD
Tacrolimus—Malnutrition—Temozolomide—melanoma	0.000136	0.000854	CcSEcCtD
Tacrolimus—Breast disorder—Docetaxel—melanoma	0.000136	0.000852	CcSEcCtD
Tacrolimus—Discomfort—Bleomycin—melanoma	0.000135	0.000851	CcSEcCtD
Tacrolimus—Malaise—Dactinomycin—melanoma	0.000135	0.000851	CcSEcCtD
Tacrolimus—Cramp muscle—Docetaxel—melanoma	0.000135	0.000849	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000135	0.000849	CcSEcCtD
Tacrolimus—Leukopenia—Dactinomycin—melanoma	0.000134	0.000845	CcSEcCtD
Tacrolimus—Dysgeusia—Temozolomide—melanoma	0.000133	0.000836	CcSEcCtD
Tacrolimus—Confusional state—Bleomycin—melanoma	0.000132	0.000833	CcSEcCtD
Tacrolimus—Vision blurred—Carmustine—melanoma	0.000132	0.000833	CcSEcCtD
Tacrolimus—Tremor—Carmustine—melanoma	0.000132	0.000828	CcSEcCtD
Tacrolimus—Oedema—Bleomycin—melanoma	0.000131	0.000826	CcSEcCtD
Tacrolimus—Anaphylactic shock—Bleomycin—melanoma	0.000131	0.000826	CcSEcCtD
Tacrolimus—Back pain—Temozolomide—melanoma	0.000131	0.000826	CcSEcCtD
Tacrolimus—Infection—Bleomycin—melanoma	0.000131	0.000821	CcSEcCtD
Tacrolimus—Anaemia—Carmustine—melanoma	0.00013	0.000817	CcSEcCtD
Tacrolimus—Dysphagia—Docetaxel—melanoma	0.00013	0.000815	CcSEcCtD
Tacrolimus—Agitation—Carmustine—melanoma	0.000129	0.000812	CcSEcCtD
Tacrolimus—Nausea—Vemurafenib—melanoma	0.000129	0.00081	CcSEcCtD
Tacrolimus—Thrombocytopenia—Bleomycin—melanoma	0.000129	0.000809	CcSEcCtD
Tacrolimus—Vision blurred—Temozolomide—melanoma	0.000128	0.000805	CcSEcCtD
Tacrolimus—Myalgia—Dactinomycin—melanoma	0.000128	0.000804	CcSEcCtD
Tacrolimus—Tremor—Temozolomide—melanoma	0.000127	0.0008	CcSEcCtD
Tacrolimus—Discomfort—Dactinomycin—melanoma	0.000126	0.000794	CcSEcCtD
Tacrolimus—Angina pectoris—Docetaxel—melanoma	0.000126	0.000794	CcSEcCtD
Tacrolimus—Ill-defined disorder—Temozolomide—melanoma	0.000126	0.000792	CcSEcCtD
Tacrolimus—Leukopenia—Carmustine—melanoma	0.000126	0.000791	CcSEcCtD
Tacrolimus—Anaemia—Temozolomide—melanoma	0.000126	0.000789	CcSEcCtD
Tacrolimus—Anorexia—Bleomycin—melanoma	0.000125	0.000787	CcSEcCtD
Tacrolimus—Agitation—Temozolomide—melanoma	0.000125	0.000785	CcSEcCtD
Tacrolimus—Pancytopenia—Docetaxel—melanoma	0.000123	0.000774	CcSEcCtD
Tacrolimus—Hypotension—Bleomycin—melanoma	0.000123	0.000772	CcSEcCtD
Tacrolimus—Oedema—Dactinomycin—melanoma	0.000123	0.00077	CcSEcCtD
Tacrolimus—Malaise—Temozolomide—melanoma	0.000122	0.00077	CcSEcCtD
Tacrolimus—Vertigo—Temozolomide—melanoma	0.000122	0.000767	CcSEcCtD
Tacrolimus—Convulsion—Carmustine—melanoma	0.000122	0.000765	CcSEcCtD
Tacrolimus—Infection—Dactinomycin—melanoma	0.000122	0.000765	CcSEcCtD
Tacrolimus—Leukopenia—Temozolomide—melanoma	0.000122	0.000764	CcSEcCtD
Tacrolimus—Hypertension—Carmustine—melanoma	0.000121	0.000763	CcSEcCtD
Tacrolimus—Neutropenia—Docetaxel—melanoma	0.000121	0.000762	CcSEcCtD
Tacrolimus—Palpitations—Temozolomide—melanoma	0.00012	0.000754	CcSEcCtD
Tacrolimus—Thrombocytopenia—Dactinomycin—melanoma	0.00012	0.000754	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Bleomycin—melanoma	0.00012	0.000753	CcSEcCtD
Tacrolimus—Chest pain—Carmustine—melanoma	0.00012	0.000752	CcSEcCtD
Tacrolimus—Myalgia—Carmustine—melanoma	0.00012	0.000752	CcSEcCtD
Tacrolimus—Anxiety—Carmustine—melanoma	0.000119	0.00075	CcSEcCtD
Tacrolimus—Cough—Temozolomide—melanoma	0.000119	0.000745	CcSEcCtD
Tacrolimus—Paraesthesia—Bleomycin—melanoma	0.000118	0.000742	CcSEcCtD
Tacrolimus—Weight increased—Docetaxel—melanoma	0.000118	0.000742	CcSEcCtD
Tacrolimus—Convulsion—Temozolomide—melanoma	0.000118	0.00074	CcSEcCtD
Tacrolimus—Weight decreased—Docetaxel—melanoma	0.000117	0.000737	CcSEcCtD
Tacrolimus—Hypertension—Temozolomide—melanoma	0.000117	0.000737	CcSEcCtD
Tacrolimus—Dyspnoea—Bleomycin—melanoma	0.000117	0.000736	CcSEcCtD
Tacrolimus—Anorexia—Dactinomycin—melanoma	0.000117	0.000734	CcSEcCtD
Tacrolimus—Pneumonia—Docetaxel—melanoma	0.000116	0.000731	CcSEcCtD
Tacrolimus—Confusional state—Carmustine—melanoma	0.000116	0.000727	CcSEcCtD
Tacrolimus—Arthralgia—Temozolomide—melanoma	0.000116	0.000727	CcSEcCtD
Tacrolimus—Myalgia—Temozolomide—melanoma	0.000116	0.000727	CcSEcCtD
Tacrolimus—Infestation NOS—Docetaxel—melanoma	0.000116	0.000727	CcSEcCtD
Tacrolimus—Infestation—Docetaxel—melanoma	0.000116	0.000727	CcSEcCtD
Tacrolimus—Anxiety—Temozolomide—melanoma	0.000115	0.000724	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000115	0.000722	CcSEcCtD
Tacrolimus—Oedema—Carmustine—melanoma	0.000115	0.000721	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000115	0.00072	CcSEcCtD
Tacrolimus—Discomfort—Temozolomide—melanoma	0.000114	0.000718	CcSEcCtD
Tacrolimus—Decreased appetite—Bleomycin—melanoma	0.000114	0.000718	CcSEcCtD
Tacrolimus—Infection—Carmustine—melanoma	0.000114	0.000716	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Docetaxel—melanoma	0.000114	0.000716	CcSEcCtD
Tacrolimus—Renal failure—Docetaxel—melanoma	0.000114	0.000714	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Docetaxel—melanoma	0.000113	0.000712	CcSEcCtD
Tacrolimus—Myocardial infarction—Docetaxel—melanoma	0.000113	0.000712	CcSEcCtD
Tacrolimus—Dry mouth—Temozolomide—melanoma	0.000113	0.000711	CcSEcCtD
Tacrolimus—Stomatitis—Docetaxel—melanoma	0.000113	0.000708	CcSEcCtD
Tacrolimus—Jaundice—Docetaxel—melanoma	0.000113	0.000708	CcSEcCtD
Tacrolimus—Pain—Bleomycin—melanoma	0.000112	0.000706	CcSEcCtD
Tacrolimus—Conjunctivitis—Docetaxel—melanoma	0.000112	0.000706	CcSEcCtD
Tacrolimus—Thrombocytopenia—Carmustine—melanoma	0.000112	0.000706	CcSEcCtD
Tacrolimus—Tachycardia—Carmustine—melanoma	0.000112	0.000704	CcSEcCtD
Tacrolimus—Confusional state—Temozolomide—melanoma	0.000112	0.000703	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000112	0.000702	CcSEcCtD
Tacrolimus—Oedema—Temozolomide—melanoma	0.000111	0.000697	CcSEcCtD
Tacrolimus—Anaphylactic shock—Temozolomide—melanoma	0.000111	0.000697	CcSEcCtD
Tacrolimus—Infection—Temozolomide—melanoma	0.00011	0.000692	CcSEcCtD
Tacrolimus—Anorexia—Carmustine—melanoma	0.000109	0.000687	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Docetaxel—melanoma	0.000109	0.000687	CcSEcCtD
Tacrolimus—Epistaxis—Docetaxel—melanoma	0.000109	0.000685	CcSEcCtD
Tacrolimus—Nervous system disorder—Temozolomide—melanoma	0.000109	0.000683	CcSEcCtD
Tacrolimus—Thrombocytopenia—Temozolomide—melanoma	0.000109	0.000682	CcSEcCtD
Tacrolimus—Feeling abnormal—Bleomycin—melanoma	0.000108	0.000681	CcSEcCtD
Tacrolimus—Agranulocytosis—Docetaxel—melanoma	0.000108	0.000678	CcSEcCtD
Tacrolimus—Skin disorder—Temozolomide—melanoma	0.000108	0.000677	CcSEcCtD
Tacrolimus—Hypotension—Carmustine—melanoma	0.000107	0.000674	CcSEcCtD
Tacrolimus—Hyperhidrosis—Temozolomide—melanoma	0.000107	0.000674	CcSEcCtD
Tacrolimus—Decreased appetite—Dactinomycin—melanoma	0.000107	0.00067	CcSEcCtD
Tacrolimus—ABCB1—lymph node—melanoma	0.000106	0.00205	CbGeAlD
Tacrolimus—Fatigue—Dactinomycin—melanoma	0.000106	0.000664	CcSEcCtD
Tacrolimus—Anorexia—Temozolomide—melanoma	0.000106	0.000664	CcSEcCtD
Tacrolimus—Pain—Dactinomycin—melanoma	0.000105	0.000659	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Carmustine—melanoma	0.000104	0.000657	CcSEcCtD
Tacrolimus—Urticaria—Bleomycin—melanoma	0.000104	0.000656	CcSEcCtD
Tacrolimus—Haemoglobin—Docetaxel—melanoma	0.000104	0.000656	CcSEcCtD
Tacrolimus—Rhinitis—Docetaxel—melanoma	0.000104	0.000654	CcSEcCtD
Tacrolimus—Body temperature increased—Bleomycin—melanoma	0.000104	0.000653	CcSEcCtD
Tacrolimus—Haemorrhage—Docetaxel—melanoma	0.000104	0.000652	CcSEcCtD
Tacrolimus—Hepatitis—Docetaxel—melanoma	0.000104	0.000652	CcSEcCtD
Tacrolimus—Insomnia—Carmustine—melanoma	0.000104	0.000652	CcSEcCtD
Tacrolimus—Hypoaesthesia—Docetaxel—melanoma	0.000103	0.000649	CcSEcCtD
Tacrolimus—Paraesthesia—Carmustine—melanoma	0.000103	0.000647	CcSEcCtD
Tacrolimus—Pharyngitis—Docetaxel—melanoma	0.000103	0.000647	CcSEcCtD
Tacrolimus—Urinary tract disorder—Docetaxel—melanoma	0.000102	0.000644	CcSEcCtD
Tacrolimus—Dyspnoea—Carmustine—melanoma	0.000102	0.000643	CcSEcCtD
Tacrolimus—Oedema peripheral—Docetaxel—melanoma	0.000102	0.000642	CcSEcCtD
Tacrolimus—Somnolence—Carmustine—melanoma	0.000102	0.000641	CcSEcCtD
Tacrolimus—Connective tissue disorder—Docetaxel—melanoma	0.000102	0.000641	CcSEcCtD
Tacrolimus—Urethral disorder—Docetaxel—melanoma	0.000102	0.000639	CcSEcCtD
Tacrolimus—Feeling abnormal—Dactinomycin—melanoma	0.000101	0.000635	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Temozolomide—melanoma	0.000101	0.000635	CcSEcCtD
Tacrolimus—Insomnia—Temozolomide—melanoma	0.0001	0.00063	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dactinomycin—melanoma	0.0001	0.00063	CcSEcCtD
Tacrolimus—Visual impairment—Docetaxel—melanoma	0.0001	0.000629	CcSEcCtD
Tacrolimus—Decreased appetite—Carmustine—melanoma	9.97e-05	0.000627	CcSEcCtD
Tacrolimus—Paraesthesia—Temozolomide—melanoma	9.95e-05	0.000626	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Carmustine—melanoma	9.9e-05	0.000622	CcSEcCtD
Tacrolimus—Dyspnoea—Temozolomide—melanoma	9.88e-05	0.000621	CcSEcCtD
Tacrolimus—Somnolence—Temozolomide—melanoma	9.85e-05	0.000619	CcSEcCtD
Tacrolimus—Erythema multiforme—Docetaxel—melanoma	9.81e-05	0.000617	CcSEcCtD
Tacrolimus—Constipation—Carmustine—melanoma	9.81e-05	0.000617	CcSEcCtD
Tacrolimus—Pain—Carmustine—melanoma	9.81e-05	0.000617	CcSEcCtD
Tacrolimus—Dyspepsia—Temozolomide—melanoma	9.76e-05	0.000613	CcSEcCtD
Tacrolimus—Eye disorder—Docetaxel—melanoma	9.7e-05	0.000609	CcSEcCtD
Tacrolimus—Abdominal pain—Dactinomycin—melanoma	9.69e-05	0.000609	CcSEcCtD
Tacrolimus—Body temperature increased—Dactinomycin—melanoma	9.69e-05	0.000609	CcSEcCtD
Tacrolimus—Hypersensitivity—Bleomycin—melanoma	9.68e-05	0.000609	CcSEcCtD
Tacrolimus—Decreased appetite—Temozolomide—melanoma	9.64e-05	0.000606	CcSEcCtD
Tacrolimus—Cardiac disorder—Docetaxel—melanoma	9.63e-05	0.000605	CcSEcCtD
Tacrolimus—Flushing—Docetaxel—melanoma	9.63e-05	0.000605	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Temozolomide—melanoma	9.57e-05	0.000602	CcSEcCtD
Tacrolimus—Fatigue—Temozolomide—melanoma	9.56e-05	0.000601	CcSEcCtD
Tacrolimus—Pain—Temozolomide—melanoma	9.48e-05	0.000596	CcSEcCtD
Tacrolimus—Constipation—Temozolomide—melanoma	9.48e-05	0.000596	CcSEcCtD
Tacrolimus—Feeling abnormal—Carmustine—melanoma	9.45e-05	0.000594	CcSEcCtD
Tacrolimus—Asthenia—Bleomycin—melanoma	9.43e-05	0.000593	CcSEcCtD
Tacrolimus—Angiopathy—Docetaxel—melanoma	9.41e-05	0.000592	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Carmustine—melanoma	9.38e-05	0.00059	CcSEcCtD
Tacrolimus—Immune system disorder—Docetaxel—melanoma	9.37e-05	0.000589	CcSEcCtD
Tacrolimus—Mediastinal disorder—Docetaxel—melanoma	9.35e-05	0.000588	CcSEcCtD
Tacrolimus—Chills—Docetaxel—melanoma	9.31e-05	0.000585	CcSEcCtD
Tacrolimus—Pruritus—Bleomycin—melanoma	9.3e-05	0.000584	CcSEcCtD
Tacrolimus—Arrhythmia—Docetaxel—melanoma	9.27e-05	0.000583	CcSEcCtD
Tacrolimus—Alopecia—Docetaxel—melanoma	9.17e-05	0.000576	CcSEcCtD
Tacrolimus—Feeling abnormal—Temozolomide—melanoma	9.13e-05	0.000574	CcSEcCtD
Tacrolimus—Mental disorder—Docetaxel—melanoma	9.09e-05	0.000571	CcSEcCtD
Tacrolimus—Abdominal pain—Carmustine—melanoma	9.07e-05	0.00057	CcSEcCtD
Tacrolimus—Body temperature increased—Carmustine—melanoma	9.07e-05	0.00057	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Temozolomide—melanoma	9.06e-05	0.00057	CcSEcCtD
Tacrolimus—Malnutrition—Docetaxel—melanoma	9.03e-05	0.000568	CcSEcCtD
Tacrolimus—Erythema—Docetaxel—melanoma	9.03e-05	0.000568	CcSEcCtD
Tacrolimus—Hypersensitivity—Dactinomycin—melanoma	9.03e-05	0.000568	CcSEcCtD
Tacrolimus—Dysgeusia—Docetaxel—melanoma	8.84e-05	0.000556	CcSEcCtD
Tacrolimus—Urticaria—Temozolomide—melanoma	8.81e-05	0.000554	CcSEcCtD
Tacrolimus—Asthenia—Dactinomycin—melanoma	8.79e-05	0.000553	CcSEcCtD
Tacrolimus—Abdominal pain—Temozolomide—melanoma	8.76e-05	0.000551	CcSEcCtD
Tacrolimus—Body temperature increased—Temozolomide—melanoma	8.76e-05	0.000551	CcSEcCtD
Tacrolimus—Back pain—Docetaxel—melanoma	8.74e-05	0.000549	CcSEcCtD
Tacrolimus—Muscle spasms—Docetaxel—melanoma	8.68e-05	0.000546	CcSEcCtD
Tacrolimus—Hypersensitivity—Carmustine—melanoma	8.45e-05	0.000531	CcSEcCtD
Tacrolimus—Diarrhoea—Dactinomycin—melanoma	8.38e-05	0.000527	CcSEcCtD
Tacrolimus—Vomiting—Bleomycin—melanoma	8.35e-05	0.000525	CcSEcCtD
Tacrolimus—Anaemia—Docetaxel—melanoma	8.35e-05	0.000525	CcSEcCtD
Tacrolimus—Rash—Bleomycin—melanoma	8.29e-05	0.000521	CcSEcCtD
Tacrolimus—Dermatitis—Bleomycin—melanoma	8.28e-05	0.00052	CcSEcCtD
Tacrolimus—Asthenia—Carmustine—melanoma	8.23e-05	0.000517	CcSEcCtD
Tacrolimus—Hypersensitivity—Temozolomide—melanoma	8.17e-05	0.000513	CcSEcCtD
Tacrolimus—Syncope—Docetaxel—melanoma	8.1e-05	0.000509	CcSEcCtD
Tacrolimus—Leukopenia—Docetaxel—melanoma	8.08e-05	0.000508	CcSEcCtD
Tacrolimus—Palpitations—Docetaxel—melanoma	7.98e-05	0.000502	CcSEcCtD
Tacrolimus—Asthenia—Temozolomide—melanoma	7.95e-05	0.0005	CcSEcCtD
Tacrolimus—Loss of consciousness—Docetaxel—melanoma	7.94e-05	0.000499	CcSEcCtD
Tacrolimus—Cough—Docetaxel—melanoma	7.88e-05	0.000495	CcSEcCtD
Tacrolimus—Diarrhoea—Carmustine—melanoma	7.85e-05	0.000493	CcSEcCtD
Tacrolimus—Pruritus—Temozolomide—melanoma	7.84e-05	0.000493	CcSEcCtD
Tacrolimus—Convulsion—Docetaxel—melanoma	7.83e-05	0.000492	CcSEcCtD
Tacrolimus—Nausea—Bleomycin—melanoma	7.8e-05	0.000491	CcSEcCtD
Tacrolimus—Hypertension—Docetaxel—melanoma	7.8e-05	0.00049	CcSEcCtD
Tacrolimus—Vomiting—Dactinomycin—melanoma	7.79e-05	0.00049	CcSEcCtD
Tacrolimus—Rash—Dactinomycin—melanoma	7.73e-05	0.000486	CcSEcCtD
Tacrolimus—Arthralgia—Docetaxel—melanoma	7.69e-05	0.000483	CcSEcCtD
Tacrolimus—Myalgia—Docetaxel—melanoma	7.69e-05	0.000483	CcSEcCtD
Tacrolimus—Chest pain—Docetaxel—melanoma	7.69e-05	0.000483	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	7.64e-05	0.00048	CcSEcCtD
Tacrolimus—Dizziness—Carmustine—melanoma	7.58e-05	0.000477	CcSEcCtD
Tacrolimus—Diarrhoea—Temozolomide—melanoma	7.58e-05	0.000477	CcSEcCtD
Tacrolimus—Dry mouth—Docetaxel—melanoma	7.52e-05	0.000473	CcSEcCtD
Tacrolimus—Confusional state—Docetaxel—melanoma	7.43e-05	0.000467	CcSEcCtD
Tacrolimus—Anaphylactic shock—Docetaxel—melanoma	7.37e-05	0.000463	CcSEcCtD
Tacrolimus—Oedema—Docetaxel—melanoma	7.37e-05	0.000463	CcSEcCtD
Tacrolimus—Dizziness—Temozolomide—melanoma	7.33e-05	0.000461	CcSEcCtD
Tacrolimus—Infection—Docetaxel—melanoma	7.32e-05	0.00046	CcSEcCtD
Tacrolimus—Vomiting—Carmustine—melanoma	7.29e-05	0.000458	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—melanoma	7.28e-05	0.000458	CcSEcCtD
Tacrolimus—Shock—Docetaxel—melanoma	7.25e-05	0.000456	CcSEcCtD
Tacrolimus—Rash—Carmustine—melanoma	7.23e-05	0.000455	CcSEcCtD
Tacrolimus—Nervous system disorder—Docetaxel—melanoma	7.23e-05	0.000454	CcSEcCtD
Tacrolimus—Dermatitis—Carmustine—melanoma	7.23e-05	0.000454	CcSEcCtD
Tacrolimus—Thrombocytopenia—Docetaxel—melanoma	7.22e-05	0.000454	CcSEcCtD
Tacrolimus—Tachycardia—Docetaxel—melanoma	7.19e-05	0.000452	CcSEcCtD
Tacrolimus—Headache—Carmustine—melanoma	7.19e-05	0.000452	CcSEcCtD
Tacrolimus—Skin disorder—Docetaxel—melanoma	7.16e-05	0.00045	CcSEcCtD
Tacrolimus—Vomiting—Temozolomide—melanoma	7.05e-05	0.000443	CcSEcCtD
Tacrolimus—Anorexia—Docetaxel—melanoma	7.03e-05	0.000442	CcSEcCtD
Tacrolimus—Rash—Temozolomide—melanoma	6.99e-05	0.000439	CcSEcCtD
Tacrolimus—Dermatitis—Temozolomide—melanoma	6.98e-05	0.000439	CcSEcCtD
Tacrolimus—Headache—Temozolomide—melanoma	6.94e-05	0.000436	CcSEcCtD
Tacrolimus—Hypotension—Docetaxel—melanoma	6.89e-05	0.000433	CcSEcCtD
Tacrolimus—Nausea—Carmustine—melanoma	6.81e-05	0.000428	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Docetaxel—melanoma	6.72e-05	0.000422	CcSEcCtD
Tacrolimus—Insomnia—Docetaxel—melanoma	6.67e-05	0.000419	CcSEcCtD
Tacrolimus—Paraesthesia—Docetaxel—melanoma	6.62e-05	0.000416	CcSEcCtD
Tacrolimus—Nausea—Temozolomide—melanoma	6.58e-05	0.000414	CcSEcCtD
Tacrolimus—Dyspnoea—Docetaxel—melanoma	6.57e-05	0.000413	CcSEcCtD
Tacrolimus—Somnolence—Docetaxel—melanoma	6.55e-05	0.000412	CcSEcCtD
Tacrolimus—Dyspepsia—Docetaxel—melanoma	6.49e-05	0.000408	CcSEcCtD
Tacrolimus—Decreased appetite—Docetaxel—melanoma	6.41e-05	0.000403	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Docetaxel—melanoma	6.36e-05	0.0004	CcSEcCtD
Tacrolimus—Fatigue—Docetaxel—melanoma	6.36e-05	0.000399	CcSEcCtD
Tacrolimus—Pain—Docetaxel—melanoma	6.3e-05	0.000396	CcSEcCtD
Tacrolimus—Constipation—Docetaxel—melanoma	6.3e-05	0.000396	CcSEcCtD
Tacrolimus—Feeling abnormal—Docetaxel—melanoma	6.07e-05	0.000382	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Docetaxel—melanoma	6.03e-05	0.000379	CcSEcCtD
Tacrolimus—Body temperature increased—Docetaxel—melanoma	5.83e-05	0.000366	CcSEcCtD
Tacrolimus—Abdominal pain—Docetaxel—melanoma	5.83e-05	0.000366	CcSEcCtD
Tacrolimus—Hypersensitivity—Docetaxel—melanoma	5.43e-05	0.000341	CcSEcCtD
Tacrolimus—Asthenia—Docetaxel—melanoma	5.29e-05	0.000332	CcSEcCtD
Tacrolimus—Pruritus—Docetaxel—melanoma	5.22e-05	0.000328	CcSEcCtD
Tacrolimus—Diarrhoea—Docetaxel—melanoma	5.04e-05	0.000317	CcSEcCtD
Tacrolimus—Dizziness—Docetaxel—melanoma	4.87e-05	0.000306	CcSEcCtD
Tacrolimus—Vomiting—Docetaxel—melanoma	4.69e-05	0.000295	CcSEcCtD
Tacrolimus—Rash—Docetaxel—melanoma	4.65e-05	0.000292	CcSEcCtD
Tacrolimus—Dermatitis—Docetaxel—melanoma	4.64e-05	0.000292	CcSEcCtD
Tacrolimus—Headache—Docetaxel—melanoma	4.62e-05	0.00029	CcSEcCtD
Tacrolimus—Nausea—Docetaxel—melanoma	4.38e-05	0.000275	CcSEcCtD
Tacrolimus—ALB—Hemostasis—PIK3CD—melanoma	6.24e-06	4.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	6.23e-06	4.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAP2K1—melanoma	6.19e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC6A11—melanoma	6.18e-06	4.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIP4K2A—melanoma	6.18e-06	4.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—FASN—melanoma	6.18e-06	4.13e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—melanoma	6.18e-06	4.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CD—melanoma	6.15e-06	4.11e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—melanoma	6.13e-06	4.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SPP1—melanoma	6.13e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—melanoma	6.13e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	6.12e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—melanoma	6.12e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAP2K2—melanoma	6.11e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC5A5—melanoma	6.08e-06	4.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—melanoma	6.07e-06	4.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2—melanoma	6.05e-06	4.05e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAPK1—melanoma	6.04e-06	4.04e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—melanoma	6.04e-06	4.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTAP—melanoma	6.01e-06	4.02e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—melanoma	6e-06	4.01e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—VCAN—melanoma	5.98e-06	4e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—melanoma	5.97e-06	4e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MDM2—melanoma	5.96e-06	3.99e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—melanoma	5.91e-06	3.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PRKCA—melanoma	5.9e-06	3.95e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FGF2—melanoma	5.88e-06	3.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—melanoma	5.88e-06	3.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNAQ—melanoma	5.87e-06	3.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CD44—melanoma	5.87e-06	3.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ERCC2—melanoma	5.85e-06	3.92e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—melanoma	5.83e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—melanoma	5.81e-06	3.89e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—melanoma	5.81e-06	3.89e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CB—melanoma	5.8e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—melanoma	5.8e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RAC1—melanoma	5.79e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—melanoma	5.79e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1A—melanoma	5.78e-06	3.87e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—melanoma	5.76e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP17A1—melanoma	5.76e-06	3.85e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NFKB1—melanoma	5.74e-06	3.84e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—melanoma	5.71e-06	3.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	5.68e-06	3.8e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP1B1—melanoma	5.63e-06	3.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—melanoma	5.62e-06	3.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—melanoma	5.56e-06	3.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—melanoma	5.51e-06	3.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1B—melanoma	5.44e-06	3.64e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNA11—melanoma	5.44e-06	3.64e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CB—melanoma	5.44e-06	3.64e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—melanoma	5.43e-06	3.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—melanoma	5.39e-06	3.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—melanoma	5.38e-06	3.6e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—melanoma	5.37e-06	3.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CB—melanoma	5.36e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PHGDH—melanoma	5.36e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LUM—melanoma	5.36e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—melanoma	5.35e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—melanoma	5.33e-06	3.57e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—FASN—melanoma	5.32e-06	3.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—melanoma	5.31e-06	3.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—melanoma	5.31e-06	3.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPSE—melanoma	5.25e-06	3.52e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	5.25e-06	3.51e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—melanoma	5.24e-06	3.51e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC5A5—melanoma	5.23e-06	3.5e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—melanoma	5.21e-06	3.48e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	5.17e-06	3.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CUBN—melanoma	5.16e-06	3.45e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—melanoma	5.15e-06	3.45e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—melanoma	5.14e-06	3.44e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—melanoma	5.14e-06	3.44e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—melanoma	5.14e-06	3.44e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FN1—melanoma	5.12e-06	3.42e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—melanoma	5.07e-06	3.39e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD44—melanoma	5.05e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNAQ—melanoma	5.05e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP17A1—melanoma	5.04e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1B—melanoma	5.03e-06	3.36e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—melanoma	5.02e-06	3.36e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—melanoma	5.01e-06	3.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—melanoma	5.01e-06	3.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—melanoma	4.99e-06	3.34e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NFKB1—melanoma	4.99e-06	3.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CSPG4—melanoma	4.98e-06	3.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BSG—melanoma	4.98e-06	3.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SDHD—melanoma	4.98e-06	3.33e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—melanoma	4.96e-06	3.32e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.95e-06	3.31e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK3—melanoma	4.92e-06	3.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD80—melanoma	4.9e-06	3.28e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.9e-06	3.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—melanoma	4.9e-06	3.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—melanoma	4.9e-06	3.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APC—melanoma	4.9e-06	3.28e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—melanoma	4.85e-06	3.25e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1B1—melanoma	4.85e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGF—melanoma	4.84e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPAM—melanoma	4.82e-06	3.23e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—melanoma	4.79e-06	3.21e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNA11—melanoma	4.76e-06	3.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—melanoma	4.76e-06	3.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—melanoma	4.75e-06	3.18e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—melanoma	4.74e-06	3.17e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK1—melanoma	4.69e-06	3.14e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—melanoma	4.68e-06	3.13e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	4.67e-06	3.13e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—FASN—melanoma	4.66e-06	3.12e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—melanoma	4.64e-06	3.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—melanoma	4.64e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCB1—melanoma	4.63e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—melanoma	4.63e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—melanoma	4.62e-06	3.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—melanoma	4.6e-06	3.08e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC5A5—melanoma	4.59e-06	3.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—melanoma	4.48e-06	3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—melanoma	4.48e-06	3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—melanoma	4.47e-06	2.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—melanoma	4.46e-06	2.98e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNAQ—melanoma	4.43e-06	2.96e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD44—melanoma	4.43e-06	2.96e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—melanoma	4.43e-06	2.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAP2K1—melanoma	4.33e-06	2.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—melanoma	4.3e-06	2.88e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—melanoma	4.28e-06	2.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK3—melanoma	4.28e-06	2.87e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.28e-06	2.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PRKCA—melanoma	4.26e-06	2.85e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1B1—melanoma	4.25e-06	2.84e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—melanoma	4.24e-06	2.84e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ERCC2—melanoma	4.23e-06	2.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—melanoma	4.19e-06	2.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—melanoma	4.14e-06	2.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—melanoma	4.13e-06	2.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGF2—melanoma	4.12e-06	2.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLA2G6—melanoma	4.1e-06	2.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK1—melanoma	4.08e-06	2.73e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—melanoma	4.08e-06	2.73e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—melanoma	4.07e-06	2.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—melanoma	4.06e-06	2.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK3—melanoma	4.01e-06	2.69e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—melanoma	4.01e-06	2.68e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCB1—melanoma	3.99e-06	2.67e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK3—melanoma	3.95e-06	2.65e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—melanoma	3.93e-06	2.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—melanoma	3.86e-06	2.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—melanoma	3.85e-06	2.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—melanoma	3.85e-06	2.57e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK1—melanoma	3.82e-06	2.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—melanoma	3.8e-06	2.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK1—melanoma	3.76e-06	2.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—melanoma	3.76e-06	2.52e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—melanoma	3.76e-06	2.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—melanoma	3.75e-06	2.51e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—VCAN—melanoma	3.68e-06	2.47e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PRKCA—melanoma	3.67e-06	2.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ERCC2—melanoma	3.64e-06	2.44e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—melanoma	3.61e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—melanoma	3.6e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—melanoma	3.6e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—melanoma	3.55e-06	2.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—melanoma	3.54e-06	2.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—melanoma	3.54e-06	2.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1B—melanoma	3.52e-06	2.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—melanoma	3.51e-06	2.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—melanoma	3.45e-06	2.31e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—melanoma	3.44e-06	2.31e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—melanoma	3.36e-06	2.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—melanoma	3.34e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—melanoma	3.33e-06	2.23e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—melanoma	3.32e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—melanoma	3.31e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—melanoma	3.27e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—melanoma	3.27e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—melanoma	3.26e-06	2.18e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—melanoma	3.25e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—melanoma	3.24e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKB1—melanoma	3.23e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—melanoma	3.22e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PRKCA—melanoma	3.22e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—melanoma	3.21e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ERCC2—melanoma	3.19e-06	2.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—melanoma	3.13e-06	2.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP17A1—melanoma	3.11e-06	2.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—melanoma	3.07e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—melanoma	3.06e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—melanoma	3.02e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.02e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—melanoma	2.94e-06	1.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNA11—melanoma	2.93e-06	1.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—melanoma	2.93e-06	1.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—melanoma	2.9e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—melanoma	2.9e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—melanoma	2.89e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—melanoma	2.89e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—melanoma	2.89e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—melanoma	2.88e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FASN—melanoma	2.87e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A5—melanoma	2.83e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—melanoma	2.78e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK3—melanoma	2.77e-06	1.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNAQ—melanoma	2.73e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD44—melanoma	2.73e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—melanoma	2.71e-06	1.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—melanoma	2.69e-06	1.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—melanoma	2.67e-06	1.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK1—melanoma	2.64e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—melanoma	2.63e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1B1—melanoma	2.62e-06	1.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—melanoma	2.56e-06	1.71e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—melanoma	2.54e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—melanoma	2.53e-06	1.69e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—melanoma	2.52e-06	1.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—melanoma	2.49e-06	1.67e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—melanoma	2.43e-06	1.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—melanoma	2.29e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—melanoma	2.22e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—melanoma	2.21e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—melanoma	2.21e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—melanoma	2.2e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—melanoma	2.19e-06	1.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—melanoma	2.18e-06	1.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—melanoma	2.16e-06	1.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCB1—melanoma	2.15e-06	1.44e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—melanoma	2.12e-06	1.42e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—melanoma	2.02e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PRKCA—melanoma	1.98e-06	1.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ERCC2—melanoma	1.97e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—melanoma	1.93e-06	1.29e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—melanoma	1.91e-06	1.28e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—melanoma	1.9e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—melanoma	1.87e-06	1.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—melanoma	1.76e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—melanoma	1.67e-06	1.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—melanoma	1.56e-06	1.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—melanoma	1.55e-06	1.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—melanoma	1.5e-06	1e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—melanoma	1.37e-06	9.14e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—melanoma	1.35e-06	9.02e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—melanoma	1.34e-06	8.99e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—melanoma	1.27e-06	8.53e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—melanoma	1.19e-06	7.96e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—melanoma	1.18e-06	7.89e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—melanoma	1.18e-06	7.88e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—melanoma	1.1e-06	7.35e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—melanoma	1.03e-06	6.88e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—melanoma	9.62e-07	6.44e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—melanoma	7.25e-07	4.85e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—melanoma	5.93e-07	3.97e-06	CbGpPWpGaD
